Onward is very happy to share that its affiliate Emercell has been selected recently by the French government to receive financial support for its cell-therapy project NK-001 (OT-C001)  aimed at treating cancer. This non-dilutive support will be a mix of grants and reimbursable cash advances. 

 

Emercell project, which spans from CMC, preclinical to clinical, was recommended by an independent expert committee for its high quality. The ambition of the project is fully in line with the objectives of the Health Innovation Agency plan to produce at least 20 new biomedicines by 2030. The project will be financed through the France 2030 “Biotherapies and bioproduction of innovative therapies” acceleration strategy.

 

“We are very proud and excited to have been selected by the French authorities, as a contributor to the Biotherapies and bioproduction of innovative therapies strategy”, said Patrick Henno, President of Emercell, “Bpifrance’s financial support, which complements Onward Therapeutics funding, will help to scale up and manufacture NK cells with our partner Cell-Easy, a CDMO based in Toulouse, and to conduct the preclinical studies and the first-in-human trial.”